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Protein kinase D family of second-messenger-
stimulated Ser/Thr protein kinases, consists of three 
members, PKD1 (also referred to as PKCn), PKD2, and 
PKD3 (also referred to as PKCn) [1, 2]. PKD family is 
assigned as a distinct group of calcium/calmodulin-
dependent kinases [3]. PKD1 was cloned in 1994 [4, 
5]. Studies in different experimental systems demon-
strated PKD1 involvement in the regulation of variety 
of cellular functions including cell differentiation, Golgi 
organization and function, regulation of intracellular 
traffic, cell migration, proliferation and apoptosis 
[6–11]. Previously we and others found expression of 
PKD1/PKCn in T and B lymphocytes and showed its 
activation in B cells in response to BCR or CD19 ligation 
[12]. PKD2 was identified much later — in 2001 [13]. 
The high level of homology between PKD1 and PKD2, 
and (until very recently) lack of isoform-specific anti-
bodies have not permitted clear distinction between 
PKD1 and PKD2. All studies carried with anti-PKD/
PKCn antibodies were interpreted to be specific for 
PKD1, however, these antibodies recognize both PKD1 
and PKD2. Despite high structural homology of these 
two kinases, they possess some specific characteristic 
features [2, 14, 15]. First, PKD2 is 105 kDa in size, while 
PKD1 is 120 kDa. Second, the major difference is in 
two Cys-rich regulatory domains, moreover, PKD2 has 
specific Ser-rich insert between these domains. Third, 
PKD1 was shown to have caspase-cleavage site, which 
is absent in PKD2 [11]. At the same time, both kinases 
have regulatory transphosphorylation site, and for 
both kinases phosphorylation of autophosphorylation 
site is an indicator of the level of activation [16–19]. 
The structural diversity could potentially determine 
functional differences of PKD1 and PKD2 kinases. 
That is why segregation between PKD1 and PKD2 is 
very important for understanding of overlapping but 
still distinct functions of these kinases in signal trans-
duction pathways. PKD3 expression and functions in 
lymphocytes are rather well characterized. Activation 
loop phosphorylation of PKD3 plays a critical role in 
the early steps of dynamic response to DAG produc-
tion [20–22].
The aim of this study was to carry out analysis of 
PKD1 and PKD2 expression and phosphorylation in 
normal and neoplastic lymphoid cells in situ. Evaluation 
of PKD1 and PKD2 expression and activity in lymphoid 
malignancies, which represent lymphocytes on diffe-
rent stages of maturation [23, 24], will help to clarify 
the place of these enzymes in signaling cascades in 
normal and tumor cells, and disclose the role of PKD1 
and PKD2 in lymphocyte differentiation. We chose im-
munohistochemical methods as the most adequate 
approach for studies of PKD1 and PKD2 in normal 
and malignant tissues. At the same time, biochemical 
approach helped us to answer the question whether 
PKD1 and/or PKD2 are expressed in lymphoid cells.
MATERIALS AND METHODS
PKD1 and PKD2 expression was studied in tissue 
sections of tonsils (11), reactive lymph nodes (5), 
IMMuNOHISTOcHEMIcAL STuDIES Of pROTEIN kINASE D 
(pkD) 2 ExpRESSION IN MALIgNANT HuMAN LyMpHOMAS
L.M. Kovalevska1, O.V. Yurchenko1, L.M. Shlapatska1,  
G.G. Berdova1, S.V. Mikhalap1, J. Van Lint2, S.P. Sidorenko1, * 
1Signal Transductions Laboratory, R.E. Kavetsky Institute of Experimental Pathology, Oncology and 
Radiobiology, NAS of Ukraine, Ukraine  
2Katholic University of Leuven, Belgium
Aim: To study the PKD2 expression, autophosphorylation and localization in reactive lymph nodes and tumors of lymphoid tissues. 
Materials and Methods: Specific antibodies, which recognize PKD1/2 or PKD2 and autophosphorylated PKD1/2, were used for im-
munohistochemical and biochemical studies of tonsils, reactive lymph nodes, tumor samples of non-Hodgkin’s lymphoma (NHL) and 
Hodgkin’s lymphoma (HL). Results: Immunohistochemical and biochemical analysis of PKD1 and PKD2 expression showed PKD2 
expression in tonsils, reactive lymph nodes and tumor tissues from patients with NHL and HL. Furthermore, we were not able to reveal 
PKD1 expression in studied lymphoid tissues. In tonsils and reactive lymph nodes the PKD2 expression was detected in T and B cell 
zones with highest level in germinal centers of lymphoid follicles and the maximum level of autophosphorylation in the light zones of 
the germinal centers. We found that low level of PKD2 expression and autophosphorylation was characteristic feature for mantle cell 
lymphomas, Burkitt’s lymphomas, and in 50% of CLL/small lymphocytic lymphomas. Lymphoma cells of germinal center origin and 
with activated B cell phenotype (diffuse large B cell lymphomas, HL) and anaplastic large cells lymphoma demonstrated the high level 
of PKD2 expression and autophosphorylation. Conclusions: The level of PKD2 expression and autophosphorylation in neoplastic cells 
corresponds to the expression pattern of this kinase in their normal analogs, and to the level of cell differentiation and activation. 
Key Words: PKD2, autophosphorylated PKD, immunohistochemistry, lymphocytes, non-Hodgkin’s lymphomas, Hodgkin’s lymphomas.
Received: May 25, 2006. 
*Correspondence: Fax: 38 (044) 2581656 
 E-mail: svetasid@onconet.kiev.ua 
Abbreviations used: BCR – B cell receptor; BL – Burkitt’s lym-
phoma; DLBCL — diffuse large B-cell lymphoma; GC – germinal 
center; HL – Hodgkin’s lymphoma; LPL – lymphoplasmacytic 
lymphoma; MCL – mantle cell lymphoma; NHL – non-Hodgkin’s 
lymphomas; PKD – protein kinase D; CLL/SLL – small lympho-
cytic lymphoma of B-cell origin.
Exp Oncol 2006
28, 3, 225–230
226 Experimental Oncology 28, 225–230, 2006 (September)
Burkitt’s lymphoma (3), diffuse large B-cell lymphoma 
(32), mantle cell lymphoma (4), small lymphocytic 
lymphoma of B-cell origin (8), lymphoplasmacytic 
lymphoma (4), anaplastic large cell lymphoma (5) and 
Hodgkin’s lymphomas (45).
Biopsies of all studied tissues were fixed in 
4% paraformaldehyde and embedded in paraffin. 
Sections were stained with hematoxylin and eosin 
for morphological studies. Lymphomas were classi-
fied and graded according to the WHO classification 
(2001) on the basis of combination of morphologic, 
immunophenotypic, and clinical characteristics. Im-
munophenotyping included detection of CD3, CD5, 
CD7, CD10, CD19, CD20, CD22, CD23, CD30, CD37, 
CD38, CD45, and CD68 on frozen tissue sections, as 
described earlier [25–27]. The level of proliferating 
cells was evaluated by IPO-38 expression [28].
Immunohistochemistry studies of PKD1 and PKD2 
were performed on deparaffined tissue sections. 
Expression of these isoforms of PKD kinases in tis-
sue sections was detected using rabbit anti-PKD1/2 
serum that recognized both isoforms [5]. Besides that, 
specific anti-PKD2 rabbit antibodies (Calbiochem, 
USA) were used for detection PKD2 on tissue sections. 
The level of autophosphorylated PKD2 was used as 
a criterion of activated PKD2 and was accessed with 
anti-phospho-PKD serum, which recognize conserved 
autophosphosphorylation site in PKD1 as well as in 
PKD2 [29]. 
To reduce nonspecific background, prior to spe-
cific antibodies, section were treated with normal goat 
serum and 0,1% solution of BSA. EnVision system 
(DAKO) was used in 30 min second-step incubation. 
After washing in phosphate-buffered saline peroxidase 
activity was assayed using DAB. After counterstaining 
with hematoxylin for 1–2 min, sections were embed-
ded in balm and studied by light microscope. Western 
blot analysis on cell lysates was performed with anti-
PKD1/2 and anti-PKD2 rabbit sera and anti-actin (SC, 
USA) according to the standard procedure described 
earlier [30].
RESuLTS AND DIScuSSION
We started immunohistochemical studies with rab-
bit antiserum that recognized both PKD1 and PKD2. In 
tonsils and reactive lymph nodes the PKD1/2 specific 
antibody stained T and B cell zones with highest level 
of the histochemical reaction in germinal centers of 
lymphoid follicles, whilst the lowest level of specific 
reaction was found in mantle zone of lymphoid follicles 
(Fig. 1, а). The maximum level of PKD autophosphory-
lation was observed in the light zones of the germinal 
centers. On the other hand, pPKD-negative interfol-
licular zone also contained some pPKD-positive cells 
(Fig. 1, b).
Results of immunohistochemical studies with 
anti-PKD1/2 and anti-phospho-PKD antibodies 
revealed the level of expression and phosphoryla-
tion of PKD1and PKD2, however, did not allow us to 
answer the question whether PKD1 and/or PKD2 are 
expressed in lymphoid cells. For identification of these 
kinases we used Western blot analysis. As is shown on 
Fig. 2, a, in lysates of tonsillar cells, non-Hodgkin’s 
lymphomas and Hodgkin’s lymphoma, anti-PKD1/2 
serum detected only one specific band of 105 kDa in 
size that corresponds to size of PKD2. Lysates of cell 
line HEK293T transfected with either PKD1, or PKD2 
served as controls. Western blot analysis using specific 
anti-PKD2 antiserum identified this band as a PKD2 
(Fig. 2, b). Immunohistochemical analysis of reactive 
lymph nodes and tonsils with specific anti-PKD2 anti-
bodies confirmed biochemical data.
fig. 1. Immunoperoxidase staining of formalin-fixed, paraf-
fin-embedded human tissue sections of tonsil (400X). PKD2 
expression (a); pPKD2 expression (b)
Thus, biochemical data clearly demonstrated that 
PKD2, but not a PKD1, is expressed in tonsils, reac-
tive lymph nodes and tumor tissues from patients with 
non-Hodgkin’s lymphomas and Hodgkin’s lymphoma. 
However, biochemical methods, including Western 
blot on whole tumor tissue samples, can not answer 
the question whether PKD2 is expressed in malignant 
cells. To answer this question we employed immuno-
histochemical approach. 
Histological analysis demonstrated that B cell 
chronic lymphocytic leukemia/small lymphocytic 
lymphomas(CLL/SLL) were characterized by a pro-
liferation of small lymphocytes. They represented a 
monotonous infiltration of small cells with round nuc-
lei, condensed chromatin, inconspicuous nucleoli, 
and scanty cytoplasm. Small lymphocytic neoplasms 
expressed CD5, CD19, CD20, CD23, IgM, and does 
not express CD10. Occasionally neoplastic cells ex-
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pressed CD22. IPO-38 antigen of proliferating cells 
was detected in 5–10% cells. The rather high level of 
PKD2 expression and moderate level of phosphory-
lated PKD2 was found in four cases of B cell CLL/SLL 
(Table). In three cases of CLL/SLL PKD2 level and 
phosphorylation was very low (Table).
fig. 2. Expression of PKD2 in cells lymphomas. Western blot 
analysis on whole cell lysates with anti-PKD1/2 (a) and anti-
PKD2 (b) antibodies. An anti-β-actin antibody was used as a 
loading control (c). 1 – tonsils; 2 – MCL; 3 – CLL/SLL; 4 – DLBCL; 
5 – ABC-DLBCL; 6 – HL; 7 – 293T-PKD1; 8 – 293T-PKD2
Mantle cell lymphomas (MCL) were characterized 
by proliferation of small lymphocytes with irregular 
nuclei, clumped chromatin, and sparse cytoplasm 
(normal analog — CD5+CD23- B cells from mantle 
zone). Lymphoma cells appear monotonous and were 
slightly larger than small lymphocytes (Fig. 3, a). These 
B cell neoplasms express sIgM, sIgD, CD5, CD19, 
CD20, CD22, and were negative for CD10 and CD23. 
80% of cells expressed IPO-38 that reflects the high 
level of proliferating cells. Mantle cell lymphomas had 
low level of PKD2 expression (Fig. 3, b). Not more than 
10% of tumor cells show PKD2 autophosphorylation 
(Fig. 3, c).
Burkitt’s lymphomas of “sporadic” type (BL) ex-
pressed sIgM, CD19, CD20, CD22, but were CD5 
and CD10 negative. The level of proliferating cell, as 
measure by IPO-38, was higher than 80%. Morpho-
logically, the field looked like a “starry sky” because of 
the presence of macrophages with tangible substance 
(the remains of apoptotic cells). The tumor cells had a 
high nuclear to cytoplasmic ratio. Lipid vacuoles were 
present in the cytoplasm, and multiple nucleoli-in the 
nucleus (Fig. 3, d). Malignant cell in BL showed low 
level of PKD2 expression (Fig. 3, e) and PKD2 auto-
phosphorylation (Fig. 3, f).
Diffuse large B cell lymphomas with germinal 
center phenotype (GC-DLBCL) contained large cells: 
centroblasts and immunoblasts. The nuclei appeared 
vacuolated because of nuclear chromatin accumu-
lated at the nuclear membrane (Fig. 3, g). These 
tumors were characterized by immunophenotype: 
sIgM+CD5+/-CD10-CD19+CD20+CD22+. In half of cases 
malignant cells were CD10+. The mitotic count and level 
of proliferating cells (IPO-38) were about 50% of cells. 
Diffuse large B cell lymphoma was characterized by 
the high level of PKD expression (Fig. 3, h) as well as 
PKD phosphorylation (Fig. 3, i). It is interesting that 
CD10- DLBCL were characterizedhad much higher 
level of PKD2 expression and autophosphorilation 
than CD10+ DLBCL.
Three cases were classified as diffuse large B cell 
lymphoma with activated B cell phenotype (ABC-
DLBCL). Tumor was composed of very large round, 
oval or polygonal cells with voluminous cytoplasm 
and large bizarre nuclei. Immunophenotype was: 
sIgM+CD5-CD10-CD19+CD20-CD22+CD30+. 50% 
of cells expressed IPO-38 antigen. Malignant cells 
showed surface CD150 expression with moderate 
level of SH2D1A in cytoplasm [28]. These malignant 
cells demonstrated high level of PKD2 expression and 
autophosphorylation (Table).
Lymphoplasmacytic lymphoma was characterized 
by diffuse infiltration of neoplastic lymphocytes with 
immunophenotype of B cells on the late stages of 
differentiation and also lymphoplasmacytoid cells and 
plasma cells. These cells showed high level of PKD2 
expression with moderate level of phosphorylation 
(Table).
Anaplastic large cell lymphomas (ALCL) were 
represented by large neoplastic cells with multiple 
nuclei and had immunophenotype: sIg-CD3-CD5-CD7-
CD19-CD20-CD22-CD30+CD45+. The high level of both 
PKD1/2 expression and autophosphorylation was 
found in malignant cells of this type of non-Hodgkin’s 
lymphoma (Table).
Hodgkin’s lymphoma (HL) was characterized by 
presence of Reed-Sternberg and Hodgkin’s cells 
(Fig. 3, j). These tumor cells were positive for CD30 
and negative for B cell markers, such as CD19, CD20, 
CD22, and IgM. In Hodgkin’s lymphoma a high level 
of phosphorylated PKD2 (Fig. 3, k) was detected 
only in Reed-Sternberg and Hodgkin’s cells, however 
PKD2 expression was found also in lymphocytes 
(Fig. 3, l).
Initial detection of PKD/PKCn in lymphoid cells with 
anti-PKCn antibodies, studies on T and B cells using 
antibodies that recognized both PKD1 and PKD2, and 
experiments with PKD1 transfectants contributed to 
the perception that PKD1 is expressed in human lym-
phocytes [11, 14]. However, some functional studies 
in lymphocytes contradicted this statement [33]. Our 
Table. PKD2 and phospho-PKD2 expression in non-Hodgkin’s lymphoma and Hodgkin’s lymphoma
Lymphoma Immunophenotype of malignant cells IPO-38 PKD2 pPKD2
CLL/SLL (n = 4) IgM+(weak), CD5+, CD10–, CD19+, CD20+, CD22+, CD23+ < 10% ++/+++ +
CLL/SLL (n = 3 ) IgM+(weak), CD5+, CD10–, CD19+, CD20+, CD22+, CD23+ < 10% –/+ –/+
MCL (n = 2) IgM+, CD5+, CD10–, CD19+, CD20+, CD22+, CD23– 80% –/+ –/+
BL (n = 3) IgM+, CD5–, CD10–, CD19+, CD20+, CD22+ > 80% + –/+
GC-DLBCL (n = 6) IgM+/–, CD5+/–, CD10+/–, CD19+, CD20+, CD22+ > 50% ++/+++ ++
ABC-DLBCL (n = 1) IgM+/–, CD5–, CD10–, CD19+, CD20–, CD22+, CD30+, CD150+ 50% +++ +++
LPL (n = 1) cyIgM+, CD5–, CD10–, CD19+, CD20+, CD22+ < 10% ++ +
ALCL (n = 5) sIg–CD3–CD5–CD7–CD19–CD20–CD22–CD30+, CD45+ > 70% +++ +++
HL (HRS cells) (n = 13) IgM–, CD19–, CD20–, CD22–, CD30+, CD150+ < 30% +++ ++
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studies showed that PKD2, but not PKD1 is expressed 
in human lymphocytes in reactive lymph tissues, and 
also in neoplastic cells of lymphoid origin. First, the 
size of the band in human lymphoid tissues, which is 
detected using anti-PKD1/2 serum, is 105 kDa and 
corresponds to the size of PKD2 (Fig. 2, a). Second, 
this band is specifically recognized by anti-PKD2 
serum (Fig.2, b). We also found differential PKD2 
expression in distinct zones of tonsils and reactive 
lymph nodes: the high level of PKD2 expression 
was detected in germinal centers, however, mantle 
zone cells showed low level of PKD2 expression. 
Autophosphorylated PKD2, which reflects the level 
of PKD2 activation, was expressed only in light zones 
of germinal centers (Fig.1). 
B cell malignancies are considered to arise from 
normal lymphocytes at different stages of B cell dif-
ferentiation [23, 24, 32]. At the same time it is not 
clear to which extend neoplastic cells maintain the 
molecular profile of key components of signal trans-
duction pathways that regulate multiple fundamental 
biological processes. PKD expression and activity was 
out of focus in these studies. In our report we showed 
that PKD2 expression in human lymphomas reflect 
expression of this kinase in their normal counterparts 
in corresponding lymph node areas. Thus, MCL were 
fig. 3. Immunoperoxidase staining of formalin-fixed, paraffin-embedded human tissue sections(400X). Mantle cell lymphoma: 
hematoxilin-eosin staining (a), PKD2 expression (b), pPKD2 expression (c). Burkitt’s lymphoma, sporadic form: hematoxilin-
eosin staining (d), PKD2 expression (e), pPKD2 expression (f). Diffuse large B cell lymphoma: hematoxilin-eosin staining (g), 
PKD2 expression (i), pPKD2 expression (h). Hodgkin’s lymphoma: hematoxilin-eosin staining (j), PKD2 expression (k), pPKD 
expression (l)
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characterized by the lowest PKD2 expression simi-
larly to majority of mantle zone cells in reactive lymph 
node. At the same time, DLBCL, like GC cells in lymph 
node, demonstrated high level of PKD2 expression. 
The fact that malignant cells at CD10+ DLBCL were 
characterized by lower level of PKD2 expression and 
autophosphorylation than at CD10- DLBCL, may also 
reflect different stages of B cell differentiation, CD10- 
neoplastic cells were more differentiated, than CD10+ 
cells. The highest level of PKD2 autophosphorylation 
was characteristic for ABC-DLBCL and lymphoblasts 
in light zones of GC (Fig. 3). CLL/SLL could arise from 
CD23+ naive B cells or from post-germinal center B 
lymphocytes [32, 33]. Three cases of CLL/SLL had 
very low level of PKD2 expression, and four cases — 
high level of expression and PKD2 autophosphoryla-
tion that could reflect mentioned above variants of 
CLL/SLL. LPL also had high level of PKD2 expression, 
but also demonstrated the moderate level of PKD2 
aytophosphorylation. Possible, that scattered small 
PKD2+ lymphocytes in mantle zone and lymph node 
paracortex could represent a normal counterparts 
for these variants of NHL. At the same time, PKD2 
expression and autophoshorylation in neoplastic cells 
in HL resembled the pattern in ABC-DLBCL. These 
two types of lymphomas have similar gene expression 
profile [24]. 
PKD is implicated in regulation of cell proliferation 
[32, 33]. Comparison of PKD2 expression and the level 
of proliferating cells in studied lymphomas did not re-
veal correlation between these parameters. High level 
of PKD2 expression was found in lymphomas charac-
terized by low level of proliferating cells (CLL/SLL, LPL 
and HL), as well as in high-proliferating DLBCL. On the 
other hand, other NHL with high level of proliferating 
cells (BL and MCL) had low level of PKD2 expression. 
At the same time, our data demonstrated that the level 
of PKD2 expression and autophosphorylation depends 
on activated phenotype of lymphocytes.
Taken together, our studies showed PKD2 ex-
pression in tonsils, reactive lymph nodes and tumor 
tissues from patients with NHL and HL. Furthermore, 
we were not able to reveal PKD1 expression in studied 
lymphoid tissues. The level of PKD2 expression and 
autophosphorylation in neoplastic cells corresponds 
to the expression pattern of this kinase in their normal 
analogs, and to the level of cell differentiation and 
activation. 
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ИммуногИстохИмИческИй аналИз экспрессИИ 
протеИн кИназы D 2 в злокачественных лИмфомах 
человека
Цель: изучить экспрессию, аутофосфорилирование и локализацию PKD2 в клетках реактивно измененных лимфaтических 
узлов и опухолях лимфоидной ткани. Материалы и методы: специфические антитела, распознающие PKD1/2 или PKD2 
и аутофосфорилированную PKD1/2, были использованы для иммуногистохимического и биохимического анализа клеток 
небных миндалин, реактивно измененных лимфaтических узлов, биоптатов опухолей у больных неходжкинскими злока-
чественными лимфомами (НХЛ) и лимфомой Ходжкина (ЛХ). Результаты: при иммуногистохимическом и биохимическом 
исследовании выявлена экспрессия PKD2 в клетках миндалин, гиперплазированных лимфатических узлов и различных 
гистологических форм НХЛ и ЛХ. Экспрессия PKD1 в изученных нами лимфоидных тканях выявлена не была. Экспрес-
сия PKD2 была выявлена в T- и B-клеточных зонах миндалин и реактивно измененных лимфатических узлов. Наиболее 
высокий уровень экспрессии отмечался в клетках зародышевых центров лимфоидных фолликулов, максимальный уровень 
аутофосфорилирования — в светлых зонах зародышевых центров. Обнаружено, что низкий уровень экспрессии и ауто-
фосфорилирования PKD2 является характерной особенностью лимфом из клеток мантийной зоны, лимфомы Беркитта, 
в 50% случаях  лимфом из малых лимфоцитов/ХЛЛ. Клетки лимфом, возникающих из клеток зародышевых центров с 
фенотипом активированных B-клеток (диффузная лимфома из крупных B-клеток, ЛХ), а также анапластическая круп-
ноклеточная лимфома характеризовались высоким уровнем экспрессии и аутофосфорилирования PKD2. Выводы: уровень 
экспрессии и аутофосфорилирования PKD2 в клетках новообразований соответствует особенностям экспрессии этих 
киназ в соответствующих нормальных аналогах, уровню клеточной дифференцировки клеток и их активации. 
Ключевые слова: PKD2, аутофосфорилированная PKD, иммуногистохимия, лимфоциты, неходжкинская злокачественная 
лимфома, лимфома Ходжкина.
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